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Abstract
Background—Prostate cancer is a major health issue, and prevention of prostate cancer and/or its
progression will yield benefits for men. Difluoromethylornithine (DFMO) is an antiproliferative
agent, inhibiting ornithine decarboxylase, the first enzyme in the polyamine pathway, and has been
studied as a therapeutic and chemopreventive agent. The prostate has high levels of tissue polyamines
and has shown sensitivity to DFMO both in vitro and in vivo.
Methods—Eighty-one men participated in a 1-year randomized trial of placebo or DFMO. Prostate
volume determination and biopsy of the prostate for histology and polyamine content were done at
baseline and after 12 months. Other biomarker variables were assessed, including total and free
prostate-specific antigen and prostate-specific antigen doubling time.
Results—Compared with baseline, men receiving DFMO had a smaller increase in prostate volume
(0.14 cm3) than those on placebo (2.95 cm3; P = 0.0301) at 1 year. In addition, DFMO caused a
60.8% reduction of prostate putrescine levels compared with a 139.5% increase in the placebo arm
(P = 0.0014). Stratification by ornithine decarboxylase genotype showed that DFMO reduced
prostate volume (P = 0.029) and putrescine levels (P = 0.0053) in the AA + GA group but not in the
GG group. There were no grade 3 or 4 toxicities. There was no clinical ototoxicity, with one
subclinical grade 2 hearing decline on audiogram.
Conclusion—In this randomized placebo-controlled trial, DFMO induced a decrease of prostate
putrescine levels and rate of prostate growth. The potential of this compound for prostate cancer or
hyperplasia should be further studied.
Introduction
Prostate cancer is the most common nonskin malignancy and the second leading cause of cancer
deaths in men. The risk for clinical prostate cancer is linked to age, race, and family history
(1). Enthusiasm for prevention of prostate cancer is based on observations of epidemiologic
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differences among prostate cancer mortality rates in Western countries compared with Asia
(e.g., Japan and China). The etiology of prostate cancer is not completely understood, and thus
there are numerous avenues of investigation under way from assessment of the genetic
contribution of the androgen receptor to the effect of the oral intake of antioxidants (2). A need
for prostate cancer prevention is predicated on the aging of society with estimates of a 4-fold
increase in the number of people over the age of 65 years by the year 2050 (1,3). As many men
choose to monitor their prostate health, chemoprevention could be used for both prevention of
prostate cancer development as well as prevention of prostate cancer progression.
Current trials for prostate cancer prevention have focused on changing the hormonal milieu
[Prostate Cancer Prevention Trial with Finasteride (4) or Reduction by Dutasteride in Prostate
Cancer Events (5)] or implementing dietary supplements linked to prostate cancer reduction
(Selenium and Vitamin E Prevention Trial; ref. 6). We have focused our attention on an agent
that is a known antiproliferative, difluoromethylornithine (DFMO). It is an irreversible
inhibitor of ornithine decarboxylase (ODC), the rate-limiting step in the conversion of ornithine
to putrescine and subsequently to the polyamines spermidine and spermine (7,8). Polyamines
are essential to cell proliferation and are tightly regulated by the cell. Elevated levels of
polyamines have been linked to carcinogenesis (9). In vitro experiments have shown this
elevation of polyamines to be closely associated and not coincidental (9-11).
The prostate has one of the highest levels of polyamines of any organ (12). The function of the
prostate is to provide fluid rich in polyamines and other compounds to the ejaculate (13). In
vitro and in vivo studies with DFMO in prostate models have shown its efficacy in decreasing
prostate polyamine levels, tumor growth, prostate growth, and regrowth (14-17). Rodents were
castrated with subsequent decrease in prostate size and polyamine content. With the return of
exogenous androgens, the prostatic atrophy was readily reversed and polyamine content was
normalized. DFMO markedly slowed prostatic weight gain from the androgens to half of the
weight of the controls and blocked increases in putrescine and spermidine levels in the prostate
(15).
Nude mouse models have shown the efficacy of DFMO in decreasing flank growth of human
xenografts of prostate cancer cell lines compared with controls (14). The transgenic
adenocarcinoma mouse prostate model has been used to test the efficacy of DFMO as a
chemoprevention agent. Gupta et al. (18) showed marked reduction in weight and volume of
the prostate as well as metastasis in the group treated with 1% DFMO. Another group reported
on the manipulation of polyamines in the transgenic adenocarcinoma mouse prostate model
by overexpression of spermidine/spermine N1-acetyltransferase, which regulates the
catabolism and export of intracellular polyamines (19). The transgenic adenocarcinoma mouse
prostate/spermidine/spermine N1-acetyltransferase animals had smaller weights of their
prostates at 30 and 36 weeks and better histologic scores. The Wistar rat model, a chemically
induced prostate cancer with methylnitrosamine/testosterone, showed a reduction in tumor
incidence to 10% to 11%, compared with controls with 64% tumor incidence, when rats were
given either oral DFMO or finasteride (20).
In humans, the genetic variability of the ODC gene, A or G at 316 (some authors label this
polymorphism at 315), has been linked to altered relative risk rates in colon polyps and prostate
cancer when exposed to differing environmental agents. Report of polyp formation in the
Aspirin/Folate Polyp Prevention Study has shown that risk of polyps was not linked to this
ODC polymorphism alone, but when combined with aspirin use, there was reduction in polyp
formation and in advanced adenomatous lesions in those participants with an A allele (21).
Martinez et al. (22) found similar results when they reviewed aspirin use and ODC genotype
status of participants in a phase III wheat bran fiber trial to reduce colon polyp recurrence. A
prostate study also showed no risk stratification for cancer based on the ODC polymorphism
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alone, but those with an A allele when linked with androgen receptor polymorphisms (CAG
repeats <22) had an odds ratio of 2 for prostate cancer. Smoking has also been linked to prostate
cancer risk in men with an A allele only (23).
We have previously shown that DFMO was able to decrease human prostate polyamine levels
in the short term (1 month) with 500 mg/m2 of oral DFMO for 28 days before rebiopsy (24).
Based on the association of polyamines with proliferation and carcinogenesis, the unique
relationship of the prostate with polyamines, and the previous laboratory and animal studies,
we set out to study longer-term use and the effect of DFMO on the prostate of men at increased
risk of prostate cancer. The primary hypothesis to be tested was whether DFMO could suppress
prostate tissue polyamine content. A secondary end point was to determine if DFMO affected
prostate size as measured by volume and if there was a differential response to DFMO in the
transitional zone compared with the total prostate.
Materials and Methods
Participants
Men ages 35 to 70 years with a family history of prostate cancer but no previous personal
history of prostate cancer were recruited to a University of California, Irvine, Investigational
Review Board–approved protocol for a phase II chemoprevention double-blind placebo-
controlled trial. Patients were screened for family history and appropriateness for inclusion.
Screening audiograms and laboratory values were done. Prerandomization biopsy and volume
measurements of the prostate were done. A minimum of six cores was taken if the prostate-
specific antigen (PSA) was within age-specific ranges and digital rectal exam was normal.
Eight to 12 cores were taken if clinically indicated. Cores were snap frozen immediately after
biopsy. After biopsy with size measurements, there was a 1-month placebo run-in period before
receiving the study drug. Pill counts were done after this 1-month period for compliance. One
participant refused to participate further after the run-in period secondary to the anxiety of
possibly receiving an experimental drug. Participants were randomized between placebo and
500 mg/d DFMO and stratified by age (<60 or >60 years) and baseline pathology report, either
benign or abnormal [i.e., prostate cancer or prostatic intraepithelial neoplasia (PIN)]. A 6-
month follow-up with laboratory values, PSA, digital rectal exam, and, if indicated, biopsy
was done. End of study biopsy was done at 12 months in the same manner as initial biopsy.
For each man, values measured at baseline served as controls for 12-month measurements.
Early in the trial, men were unexpectantly diagnosed with prostate cancer, a function of the
random tissue sampling needed for polyamine analysis. Men were given all their therapeutic
options for localized prostate cancer, weighted toward treatment due to their family history.
Those with a Gleason 4 component were strongly encouraged to receive definitive therapy.
Due to the combination of low PSA levels, or minimal core involvement, several men elected
to undergo expectant management. An amendment the second year of accrual allowed
inclusion of patients diagnosed at baseline with prostate cancer who elected expectant
management to continue participation in the trial. Over all of the 81 baseline biopsies, 11 men
had cancer and 4 went for treatment. Two men had PIN on initial biopsy. Seven men with
cancer and both men with PIN came onto the trial. The PSA ranged from 0.8 to 4.8 ng/mL. All
men but one had a PSA <2.1 ng/mL. Pathology was focal to 20%, Gleason 3 + 3 in all but one
man. He had Gleason 4 + 3 in 10% of one core and PSA of 2.1 ng/mL and refused definitive
therapy. Five men were randomized into the DFMO arm and four onto placebo. One man with
cancer randomized to DFMO did not return for end of study biopsy.
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Family History Inclusion
Inclusion to the trial required two first-degree relatives (father and brother) or more than two
second-degree or first cousins diagnosed with prostate cancer. Laboratory values are the
following: complete blood count, chemistry 20 metabolic panel, protime, urine analysis,
Hybritech PSA, and free PSA. Air conduction pure tone threshold audiograms were done at
baseline and at the end of study and upon request by the participant.
Prostate Volume and Prostate Biopsy Technique
Transrectal prostate needle biopsies were done using lateral sextant template. Volumes were
calculated by the software of the ultrasound machine incorporating imputed height, length,
transverse length of the total prostate, and the transition zone of the prostate [π / 6 × (transverse
diameter × anteroposterior diameter × cephalocaudal diameter)]. There were nine patients who
did not have both (before and after treatment) transition zone measurements taken at the time
of total prostate volume measurements. Lidocaine jelly was instilled into the rectal vault before
probe insertion, and 1% lidocaine was injected into the periprostatic tissue after volume
measurements before the biopsy. Aspirin and other anti-inflammatory medications were
stopped 5 to 10 days before biopsy, as well as dietary supplements, which might affect bleeding.
Six doses of ciprofloxacin, one every 12 h, were given starting the night before the procedure.
A Ducolox suppository was given the morning of the procedure.
Histology
Cryostat sections were stained with H&E and basal cell–specific anti-keratin 5 antibody for
diagnostic purposes. All pathology specimens were reviewed by one pathologist (R.N.) and
given a Gleason grade. Those whose initial biopsy showed PIN or atypical changes were
rebiopsied before randomization.
Polyamine Analysis
Three to six cores of snap-frozen prostate tissues were used for the polyamine analysis.
Technical aspects have been reported previously (25-30); briefly, this included standard
polyamine preparations and use of internal standards. Prostate tissue was minced in 300 μL of
9.2 N perchloric acid, homogenized vigorously with the resulting lysate stored overnight at 4°
C, and rehomogenized. The acid-insoluble fraction was collected by centrifugation and the
acid-soluble fraction with the polyamines was analyzed by high-performance liquid
chromatography using the method of Seiler and Knodgen, normalizing to protein content.
Protein levels were assayed using the bicinchoninic method.
Genetic Markers
The genotype of the ODC single nucleotide polymorphism 316 nucleotides 3′ of the
transcriptional start site of the ODC gene was measured as described earlier (22). Briefly, one
7-mL Vacutainer containing EDTA of whole blood was collected for genotyping. This sample
was aliquoted into two 2-mL cryovials and stored at −80°C until DNA was extracted. Genomic
DNA was extracted from whole blood using the QIAamp Blood DNA Mini kits from Qiagen.
Laboratory best practices, including negative and positive controls as well as duplicates, were
used to generate the ODC genotypes.
Statistical Analysis
Descriptive statistics (e.g., arithmetic means) were calculated for prostate volume and
transition zone volume. Characteristics of placebo and DFMO treatment groups were compared
using an independent sample t test for age at baseline and the log-transformed values of percent
free PSA, prostate volume, and spermine. Because of lack of normality of baseline
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distributions, the Wilcoxon two-sample test was applied to compare treatment groups with
regard to total PSA, free PSA, transitional zone, putrescine, spermidine, and the ratio of
spermidine to spermine. For putrescine, spermidine, and spermine, the relative percent
difference between corresponding values measured at 12 months and at baseline was calculated
as the ratio of the absolute difference to the baseline value multiplied by 100%.
Treatment groups were compared with regard to median relative percent difference by
Wilcoxon two-sample tests. Stratified by ODC polymorphism, GG versus GA and AA,
treatment groups were compared using nonparametric Wilcoxon two-sample tests for
putrescine and spermidine and independent sample t tests for the log transform of spermine.
We computed distribution-free 95% confidence intervals as described in Hahn and Meeker
(31). Comparisons of the absolute 12-month difference between treatment groups were based
on an independent sample t test for prostate volume and a nonparametric Wilcoxon two-sample
test for transition zone volume. Mean absolute difference of 12 months to baseline was
calculated for prostate volume (cm3) and transitional zone volume (cm3), stratified by ODC
allele, GG versus GA and AA. For analysis of transition zone volume within the GG allele, a
nonparametric Wilcoxon two-sample test was applied. Independent sample t tests were used
for all other comparisons within allele subgroups. The effect of DFMO treatment on the PSA
doubling time after 6 and 12 months was assessed as follows: let T = time in months, PSA1 =
first PSA measurement, and PSA2 = second PSA measurement. Then, PSA doubling time was
calculated as log(2) × T / [log(PSA2) − log(PSA1)]. Independent sample t tests were applied
to assess differences between treatment groups.
Results
Demographics of the Participants
The trial enrolled (signed consent forms) 140 men. The median time from study entrance to
baseline biopsy was 41 days. The median time from baseline biopsy to start of treatment was
35 days, which accounts for the 1-month run-in period. Eighty-one men underwent an initial
biopsy, 76 men were randomized, 66 completed the study with two sets of biopsies of which
62 finished with 12 months of study drug and an end of study biopsy, and the other 4 exited
the trial at 6 months when the diagnosis of cancer was made at a 6-month biopsy and treatment
options were pursued. The results reported include all men with both an entrance and exit
biopsy, regardless of cancer status. There were no significant differences at baseline or response
to treatment, although the numbers of men with cancer (six) or PIN (two) at entrance or new
cancers at exit (four) were too small to give meaningful data with substratification.
The majority (n = 57) of the participants in the clinical trial were White (75.0%), 10 (13.2%)
were African-Americans, 8 (10.5%) were Hispanic, and 1 (1.3%) was Asian. Twelve of the
participants (15.8%) were <45 years old on entry in the study, 23 (30.3%) were between the
ages of 45 and 54 years, 29 (38.2%) were between the ages of 55 and 64 years, and 12 (15.8%)
were >65 years old.
Table 1 outlines the baseline demographics of the participants randomized between the two
arms. There were no statistical differences between participants in the two arms for age, race,
cancer status, starting PSA, percent free PSA, prostate size, or polyamine levels. There were
no statistical differences on the baseline polyamines (or log-transformed values) between the
9 randomized cancer/PIN patients and the rest of the 63 patients with normal biopsy at baseline
(data not shown). Table 2 outlines the number of men in each arm with either the GG or AG/
AA allele at 316 for each variable measured. There were no statistical differences between
ODC allele type and treatment.
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Effect of DFMO on Prostate Polyamine Levels
DFMO decreased relative to baseline median putrescine levels by 60.8%, whereas the placebo
group showed a relative 139.5% increase in putrescine levels (P = 0.0014; Table 2; Fig. 1A).
When stratified by ODC genotype and comparing the subgroups with the corresponding
subgroup in the treatment arms, the men with AA and AG alleles showed a reduction in
putrescine levels with DFMO (P = 0.0053), whereas the men with the GG genotype did not
show a treatment effect (P = 0.11; Table 2; Fig. 1B).
There was no statistically significant decrease in spermidine or spermine with 12 months of
DFMO compared with placebo. However, median value of spermidine, relative to baseline,
was unchanged in the DFMO arm versus an increase by 37.1% in the placebo group (P = 0.39).
Median value, relative to baseline of spermine, decreased by 16.6% in the DFMO group versus
an 18.7% increase in the placebo group (P = 0.24; Table 2; Fig. 1A). After being stratified by
genotype, the men with the AA and AG genotype showed a trend toward relative reduction in
spermidine and spermine levels with treatment (P = 0.09 and 0.06; Table 2; Fig. 1B).
Effect of DFMO on Prostate Volume
In the DFMO arm, the prostate volume was increased by a mean of 0.14 cm3 (0.94%) compared
with a mean increase of 2.93 cm3 (11.14%) for the placebo arm (P = 0.030; Table 2; Fig. 2A).
When evaluated by ODC genotype, DFMO reduced prostate volume in the AA + GA group
(P = 0.029) but not in the GG group (P = 0.33; Table 2; Fig. 2B). When evaluating the effect
on the transition zone volume, the DFMO group showed a 0.78 cm3 increase (18.9%) in
transition zone volume and the placebo group showed a 2.93 cm3 (41.4%) increase in volume
(P = 0.35; Table 2; Fig. 2A). Studying individual genotype groups did not show an increased
efficacy in either ODC genotype (P = 0.91 for AA + GA and P = 0.38 for GG), although the
sample size was smaller for this transition zone volume end point (Table 2; Fig. 2B).
Effect of DFMO on PSA Levels
The relative percent difference (before to after study) for PSA declined by a 0.75% change in
the DFMO arm compared with an increase by 1.55% in the placebo arm. Free PSA and percent
free PSA increased by 4.4% and 10.2% in the DFMO arm compared with an increase of 0.35%
and 4.98% in the placebo arm. These changes did not achieve statistical significance (Table 2;
free PSA data not shown). PSA velocity showed a different slope between the two arms. There
was a PSA doubling time of 13.5 months for the placebo arm versus a decline in PSA doubling
time for the DFMO arm (P = 0.13). Stratification by ODC genotype did not show differences
between the treatment arms on PSA variables.
Effect of ODC Genotype on Prostate Polyamine Levels
There were no statistically significant differences of baseline putrescine (P = 0.32) values by
ODC genotype, although there were statistically significant baseline differences in spermidine
(P = 0.03) and spermine (P = 0.01) and total polyamine content (data not shown; P = 0.04).
The likely reason for this differential response is that the spermine pool is much larger than
either putrescine or spermidine in the prostate. Putrescine is likely only transiently occupied
as the amines are converted to spermine.
Side Effects
There were no grade 3 or 4 toxicities in either group as assessed by the National Cancer Institute
Common Terminology Criteria for Adverse Events version 3. There were four grade 2 toxicities
recorded during the trial: one in the DFMO arm (a subclinical hearing change on audiogram;
see below) and three in the placebo arm (rash, chest pain, and vomiting). Men reporting grade
1 toxicities were slightly higher in the DFMO group, 20 men versus 15 in the placebo group.
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A grouping of grade 1 toxicities of muscular skeletal complaints (disk disease, tendonitis, etc.)
showed more complaints in the DFMO group (seven participants versus two in the placebo
arm), although all were recorded as unlikely related to drug. One man receiving DFMO
withdrew from the study due to side effects, primarily upper gastrointestinal complaints
consistent with reflux but also erectile decline. There was no difference between the arms in
number of men complaining of sexual difficulties (three men versus two men) and
gastrointestinal side effects (four versus four) in the DFMO versus placebo arm, respectively.
The number of men with no reported side effects was similar for each group, 18 men on the
DFMO and 20 men on the placebo arm.
There were six hearing-related complaints in the placebo arm (two tinnitus, two vertigo, and
two hearing changes) and five hearing-related complaints in the DFMO arm (one tinnitus, three
vertigo, and one hearing changes). Audiograms showed a subclinical hearing change in one
participant in the DFMO arm, rated a grade 2 toxicity, secondary to the shifts of 15 dB at 2,000
and 3,000 Hz in both ears; repeat audiogram at 19 months, 7 months off study, showed the
change to be stable.
Discussion
In this 1-year randomized double-blind placebo-controlled trial of the effects of DFMO on
prostate polyamines, size, and PSA metrics, we were able to meet our primary objective in
demonstrating a decrease in prostate putrescine level, although we were unable to show
significant reduction in prostate spermidine and spermine levels as we had previously shown
in a shorter study. In addition, we showed that DFMO was able to significantly modulate the
rate of growth as measured by total prostate volume. In addition, total prostate volume and
putrescine level changes were influenced by the ODC genotype of the participants.
Previously, we have shown in a 1-month trial that all three polyamines were suppressed.
Putrescine decreased from baseline by 98% (P < 0.03), spermidine by 74% (P < 0.004), and
spermine by 51% (P < 0.004; ref. 24). Compared with previous reports with DFMO with other
types of tissues, the reduction in spermine levels in the prostate was marked in this short trial.
In the current longer trial, we were able to show continued suppression of prostate putrescine
levels. That other polyamine levels were less affected by DFMO in this trial compared with
our previous report could represent the lower dose of DFMO used in this trial (500 mg/d versus
500 mg/m2/d used in the previous trial) or other factors, such as compensation, by cells over
time by altering polyamine uptake or metabolism.
Stratification by ODC genotype showed that men with the AA or AG genotype showed
reduction in putrescine level and trends in reduction for spermidine and spermine. In contrast,
no reduction in these variables in the men with the GG genotype was seen. ODC genotyping
was not done on the previous study, so genetic comparisons between the two trials cannot be
done.
The decrease in prostatic growth over 1 year as measured by total prostate volume shown in
the men receiving DFMO, an antiproliferative agent, is intriguing (P = 0.0301). Prostatic
enlargement with age is well documented. In the Olmsted County database, an overall annual
growth rate of 1.6% was seen (32), and Berry et al. (33) reported that maximal growth was
seen in the men ages 31 to 50 years with a doubling time of 4.5 years. In our trial, the prostate
volume in participants in the placebo arm increased 11.4% compared with the DFMO arm with
an increase in size of 0.94%. The stratification of the participants into ODC genotype showed
that DFMO had an effect on total prostate volume in participants with the GA and AA genotype
but not the GG genotype when evaluating total prostate volume. Similar trends were seen in
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the transition zone, but as not all patients had both before and after transition zone
measurements (nine patients), the sample size was smaller.
The relative difference in PSA over the 12 months for the placebo group was an increase of
1.55% compared with −0.75% for the DFMO arm. Free PSA and percent free PSA increased,
respectively, 0.35% and 4.89% in the placebo arm versus a 4.39% and 10.21% increase in the
DFMO arm (Table 2). More men had stable or declining PSA while receiving DFMO (73%
versus 51%; data not shown), and PSA doubling time was altered by DFMO when compared
with control (data not shown). Current PSA usage stratifies increased prostate cancer risk to
higher total PSA levels, lower percent free PSA levels, and increased velocity (2). The PSA
changes observed in our study were not statistically significant possibly because the sample
size was too small, the baseline PSA levels were low, or DFMO does not affect PSA production.
It is interesting to consider if DFMO caused a decrease in total PSA with a positive increase
in free PSA and a decline in PSA doubling time; all trends if further substantiated would be
associated with a decline in cancer risk as currently assessed and possibly prostate cancer
(34-36).
There was no clinical ototoxicity shown during this 1-year trial of low-dose DFMO. One
subclinical grade 2 hearing decline, secondary to the shifts of 15 dB at 2,000 and 3,000 Hz in
both ears, was recorded in one patient. Ototoxicity has been linked to DFMO, particularly at
higher doses. Doses of 9 g/m have been reported to cause reversible ototoxicity, but doses <1
g/m2 have not been consistently linked to ototoxicity (8). Love et al. (37) reported a 12.5%
(three participants) incidence of reversible ototoxicity while on a 1-year trial of 0.5 g/m2/d, but
Doyle et al. (38) have not shown ototoxicity at similar doses. In addition, we have followed
more than 300 patients on a colon cancer prevention trial for up to 3 years on the same dose
of DFMO used on the current trial and there was no difference in self-reported clinical hearing
loss between patients on the treatment and placebo arms, although minimal subclinical changes
in a subset of patients were evident.7
Several trials have been conducted with DFMO for cancer treatment (39-41) and prevention
(25,42-44). Many trials have lasted less than a year and focused on dosage, toxicity, and
measurement of efficacy on surrogate end biomarkers (24,25,42,44,45). Results have been
mixed. Promising results with actinic keratosis, with total number reduction of actinic keratosis
(P = 0.001) and decreased spermine levels (P = 0.04) and decreased p53-positive cells (P =
0.04; refs. 43,46), have been overshadowed by an absence of effect with measured biomarkers
in breast and cervix trials (42,44). A current trial with DFMO in patients with prior colon polyps
but no history of colon cancer has been extended from a short-term phase II trial after showing
efficacy on surrogate end biomarkers to a 3-year phase III trial in combination with sulindac
in which the clinical end point of tumor/polyp reduction is being measured. Recent analysis
has shown a marked effect of the DFMO/sulindac in reducing adenomas and polyamines with
minimal toxicity.7 The details of the trial design are reported elsewhere (9,47).
The Aspirin/Folate Polyp Prevention Study and the secondary analysis of aspirin use in a high-
fiber cereal supplement polyp prevention trial illustrate the principle that subpopulations may
be more amenable to intervention, as polyp reduction with aspirin was significantly improved
in participants with an A allele at the ODC 315/316 position (21,22). In the colon, one working
hypothesis as to the effect this allelic polymorphism could have on colon cancer development
is that the A allele binds more readily to gene regulators than the G allele. As adenomatous
polyposis coli is lost, c-myc levels become elevated and this in turn more readily activates
ODC with an A allele at position 315/316. The G alleles are less responsive to this c-myc
7F.L. Meyskens, Jr., unpublished data.
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activation (48). The mechanism for polymorphic variation in response to DFMO as reflected
in prostate putrescine levels or prostate volume has yet to be elucidated.
The genetic causes of prostate cancer have been hard to determine and may reflect that prostate
cancer is influenced by polymorphisms in multiple pathways (androgen receptor, DNA repair
genes, steroid biosynthesis, etc.), in addition to environmental factors. Visvanathan et al.
(23) studied the prostate cancer risk using two polymorphisms, CAG repeats in the androgen
receptor and ODC 316, in addition to smoking status. The hypothesis is that ODC under control
of the androgen receptor and stimulated by nicotine may be linked to prostate cancer. They
found that an A allele and shorter CAG repeats in smokers were linked to an increased relative
risk of prostate cancer. They subsequently reported racial variations in ODC 316 frequencies
with the A allele most prevalent in Africans (0.415) and least prevalent in Hispanics (0.183;
ref. 49).
The prostate may be a better target organ for the use of DFMO as a preventive agent (50). The
function of the prostate is to provide fluid rich in polyamines to the ejaculate (13). ODC is
under androgen regulation (51). The previously outlined demonstration of high ODC activity
in the prostate and sensitivity to DFMO in laboratory studies supports the use of polyamine
reduction in the prostate as a potential biomarker for future chemopreventive trials and a
reasonable chemopreventive strategy. Our current trial shows the effectiveness of DFMO at
suppressing human polyamine content and altering the volume of the prostate. This further
raises the enthusiasm for DFMO as a potential chemopreventive agent targeting the prostate
and provides a substantial basis for larger and definitive trials.
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Figure 1.
A. Median relative percent difference of putrescine, spermidine, and spermine for placebo or
DFMO. The relative percent difference refers to the ratio of the absolute difference divided by
the baseline multiplied by 100%. Statistical tests are based on nonparametric Wilcoxon two-
sample tests. DFMO lowered putrescine levels (P = 0.0014); however, the other polyamines
did not show significant differences between treatment groups. B. Median relative percent
difference of putrescine, spermidine, and spermine for placebo or DFMO stratified by ODC
polymorphism, GG versus GA and AA. Percent relative difference is calculated as the ratio of
the absolute difference divided by the baseline value multiplied by 100%. Statistical tests for
differences between treatment groups include nonparametric Wilcoxon two-sample tests for
putrescine and spermidine and independent sample t tests for the log transform of spermine.
DFMO treatment lowered putrescine levels in the GA and AA group (P = 0.0053) but not in
the GG group (P = 0.11). The other polyamine levels did not show statistical differences by
treatment within polymorphism subgroup, although trends may be seen in the GA and AA
group for spermine (P = 0.06) and spermidine (P = 0.09) levels for treatment with DFMO.
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Figure 2.
A. Absolute 12-mo difference in prostate and transition zone volume. Columns, mean
difference of prostate volume (cm3) and transitional zone volume (cm3); bars, SE.
Comparisons between treatment groups are based on an independent sample t test for prostate
volume and a nonparametric Wilcoxon two-sample test for transition zone volume. Prostate
volume showed a treatment effect (P = 0.03). There was no significant difference between
treatment groups in mean transitional zone change (P = 0.35). B. Absolute 12-mo difference
in prostate and transition zone volume stratified by ODC genotype. Columns, mean absolute
difference of 12 mo to baseline of prostate volume (cm3) and transitional zone volume (cm3)
stratified by ODC allele, GG versus GA and AA; bars, SE. For analysis of transition zone
volume within the GG allele, a nonparametric Wilcoxon two-sample test was applied.
Independent sample t tests were used for all other comparisons within allele subgroups. Prostate
volume showed a treatment effect in the GA and AA grouping (P = 0.029) but not in the GG
group (P = 0.33). Mean transitional zone changes were not significantly different.
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